1、Reinventing R&D in the age of AIHow intelligent technologies are transforming the Biopharma IndustryContentsPage 3Preface Page 5About the researchPage 12Reinventing the R&D organization Page 30ConclusionPage 6The R&D opportunityReinventing R&D in the age of AI2About the researchThe R&D opportunityCo

2、ntentsConclusionPrefaceReinventing the R&D organizationR&D leaders across the industry are unanimous about the challenges ahead,voicing concerns like:I now have to choose between investing in an asset(a clinical trial or external innovation)vs.an emerging technology.I now have to take bigger risks t

3、o scale new technologies on high value assets because the upside is significant.I now have to consider myriad factors(such as drug access,pricing,reimbursement and manufacturing scale challenges)in conjunction with choices around modality before an asset goes into first-in-human studies.I now have t

4、o make investments that will create value in a short timescale so that I can fund essential technology and capability investments that will be critical to R&D reinvention and pay off in the longer term.PrefaceLife-changing interventions that have previously been pipedreams are now within reach for t

5、he biopharma industry,made possible through an increasingly sophisticated understanding of human biology coupled with unparalleled advances in technology.On the other hand,the industrys research and development(R&D)productivity has remained largely unchanged for a decade,while the complexities of bi

6、opharmas competitive market have continued to evolve.While intelligent technologies promise to accelerate scientific advances and address some of the fundamental R&D challenges that existed for a decade,they require capital investment and a thoughtful approach.Creating therapies from basic science a